Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Reported data for HAQ CFB, ACR-50 and DAS28 < 2.6 at 24 and 52 weeks

From: Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

Trial N Mean HAQ CFB at 24 weeks (SD) Mean HAQ CFB at 52 weeks (SD) ACR-50 r at 24 weeks ACR-50 r at 52 weeks DAS28 < 2.6 r at 24 weeks DAS28 < 2.6 r at 52 weeks
Placebo + MTX        
AIM [14, 18] 219 -0.40 (0.59) -0.37 (0.59) 37 40 6 4
Kremer et al. 2005, Kremer et al. 2003 [16, 17] 119 -0.14 (0.49*) -0.10 (0.83*) 14 24 11 12
ATTEST [15] 110 -0.29 (0.22)   22   3  
ARMADA [25] 62 -0.27 (0.57)   5    
DE019 [24] 200 -0.24 (0.52) -0.25 (0.56) 19 19   
RAPID I [26, 27, 29] 199 -0.17 (0.56) -0.18 (0.56) 15 15   
RAPID II [28, 29] 127 -0.14 (0.45)   4   1  
Weinblatt et al. 1999 [32] 30 -0.40 (0.49*)   1    
TEMPO [30, 31] 228 -0.63 (1.08*) -0.63 (1.41*) 92 91 31 39
GO-FORWARD [33, 34] 133 -0.13 (0.58)   18   8  
ATTRACT [35, 36] 88 -0.19 (0.49*) -0.17 (0.60*)   8   
DANCER [39, 40] 122 -0.28 (0.50)   16    
Strand et al. 2006 [41] 40 -0.40 (0.62*) -0.30 (0.64*) 5 2   
SERENE [37, 38] 172 -0.19 (0.56*) -0.19 (0.60*) 15 15 3 3
OPTION [43, 44] 204 -0.34 (0.83*)   22   1  
LITHE [42] 393     39   12
Abatacept + MTX        
AIM [14, 18] 433 -0.59 (0.62) -0.66 (0.62) 173 209 64 103
Kremer et al. 2005, Kremer et al. 2003 [16, 17] 115 -0.42 (0.49*) -0.47 (0.83*) 42 48 30 40
ATTEST [15] 156 -0.68 (0.22) -0.67 (0.62) 63 71 18 29
Adalimumab + MTX        
ARMADA [25] 67 -0.62 (0.63)   37    
DE019 [24] 207 -0.56 (0.52) -0.59 (0.57) 81 86   
Certolizumab + MTX        
RAPID I [26, 27, 29] 393 -0.58 (0.59) -0.60 (0.59) 146 147   
RAPID II [28, 29] 246 -0.50 (0.47)   80   23  
Etanercept + MTX        
Weinblatt et al. 1999 [32] 59 -0.70 (0.49*)   23    
TEMPO [30, 31] 231 -0.89 (1.08*) -0.97 (1.41*) 136 180 70 88
Golimumab + MTX        
GO-FORWARD [33, 34] 89 -0.47 (0.55)   33   18  
Infliximab + MTX        
ATTEST [15] 165 -0.53 (0.29) -0.59 (0.64) 61 60 21 20
ATTRACT [35, 36] 86 -0.31 (0.49*) -0.32 (0.60*)   21   
Rituximab + MTX        
DANCER [39, 40] 122 -0.49 (0.55)   41    
Strand et al. 2006 [41] 40 -0.60 (0.92*) -0.60 (0.88*) 17 14   
SERENE [37, 38] 170 -0.42 (0.54*) -0.47 (0.60*) 44 61 15 19
Tocilizumab + MTX        
OPTION [43, 44] 205 -0.55 (0.82*)   90   47  
LITHE [42] 398     145   127
  1. *Standard deviation (SD) was estimated.
  2. No placebo value was available at 52 weeks for placebo so the values have been assumed equal to the values for 24 weeks.
  3. ABA, abatacept; ADA, adalimumab; CFB, change from baseline; CZP, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; N, number of patients in trial; PBO, placebo; r, number of responders; RTX, rituximab; TCZ, tocilizumab